3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia, Lymphocytic, Chronic, B-Cell
26
Myelodysplastic Syndromes
10
Lymphoma, Mantle-Cell
8
Neoplasms
7
Leukemia, Myelomonocytic, Chronic
7
Burkitt Lymphoma
7
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Myeloproliferative Disorders
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Biphenotypic, Acute
4
Leukemia, B-Cell
4
Waldenstrom Macroglobulinemia
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Primary Myelofibrosis
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma
2
Hematologic Neoplasms
2
Hematologic Diseases
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
venetoclax
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled